RxDoctor Payments Data

Vinay Chaudhry, MD

Neurology · Lutherville, MDNPI 1447209838

Payments from drug & device makers

$61,142in general payments, 2019–2025

Across 36 payments — averaging $1698.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$48K
  • Sanofi$12K
  • Grifols Shared Services North America, Inc.$827
  • CSL Behring$523
  • UCB, Inc.$229
  • Argenx US, Inc.$59
$1,431in research payments, 2019–2025

Across 7 payments — averaging $204.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1K

What the payments were for

  • Consulting fees$11,70385%
  • Travel & lodging$4653%
  • Food & beverage$1,57811%
  • Education$230%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)13$47,596
Sanofi6$11,909
Grifols Shared Services North America, Inc.10$827
CSL Behring3$523
UCB, Inc.3$229
Argenx US, Inc.1$59

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,142 in reported general payments places this provider in the 85th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$33,836
Medicare patients
133
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirdapseAmifampridine Phosphate14$529,524
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5017$471,247
Pyridostigmine Bromide15$803
Azathioprine12$377
Gabapentin22$343
Prednisone29$203

Paid to pharmacies, not to this prescriber.

Other neurology in Lutherville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →